Abstract
EGF receptor (EGFR)-specific monoclonal antibodies (mAb) display limited therapeutic efficacy in EGFR-positive solid tumors. To overcome this limitation, the significant improvement of the antibody-dependent cell-mediated cytotoxicity-mediated antitumor activity of a novel EGFR-specific mAb is described. Its potential impact on the efficacy of immunotherapy for EGFR-positive solid tumors is discussed.
©2013 AACR.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Animals
-
Antibodies, Monoclonal / therapeutic use*
-
Antibody-Dependent Cell Cytotoxicity*
-
ErbB Receptors / antagonists & inhibitors*
-
ErbB Receptors / immunology
-
ErbB Receptors / metabolism
-
Humans
-
Neoplasms / drug therapy*
-
Neoplasms / immunology
-
Protein Kinase Inhibitors / therapeutic use*
Substances
-
Antibodies, Monoclonal
-
Protein Kinase Inhibitors
-
ErbB Receptors